Another autoimmune CAR-T death; Treasury zeroes in on China deals
A patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.
A patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.